Scale Out

With the rising demand for ATMPs, technology needs to overcome the current limitations of cell therapy manufacturing.

Our cGMP-compliant closed Systems enable the increase of productivity and the reduction of production costs, moving towards decentralized models of Advanced Therapies manufacturing.

NANT 001 and NANT XL Systems installed in the Facility of ImmunityBio (Culver City, CA) for the scale-out production of an allogeneic Mesenchymal Stem Cell (MSC) therapy to treat patients with acute respiratory distress syndrome (ARDS) caused by COVID-19.

Scale Out is a Choice

Easy Transition from the Traditional Manual Process

NANT Systems support the scale-out of cell therapy manufacturing, allowing an easier optimization of the cell expansion protocol with a reduced cell culture volume, and giving the opportunity to adjust the capacity of your facility according to the demand.

Avoiding Cross-Contamination Risks

Cross-contamination is avoided thanks to our fully closed cGMP-compliant Systems, designed to ensure the aseptic processing and cell culture expansion.

Supporting a Wide Range of ATMP Products

NANT Systems can support the production of different cell therapy processes at the same time in the same place, allowing the manufacturing of multi-product ATMPs. §4.2 and §9.4 of the Guidelines on GMP specific to ATMPs – EudraLex Vol.4 /GMP (2018)